9:36 am Tonix Pharma completes pre-IND meeting with FDA on TNX-201 for episodic tension-type headache; will not require any additional nonclinical data to support a first-in-man study; clinical development to begin in 4Q 2014
View todays social media effects on TNXP
View the latest stocks trending across Twitter. Click to view dashboard
See who Tonix is hiring next, click here to view
